

## **Alligator Bioscience to Participate in Upcoming Investor Conferences**

**Lund, Sweden, November 10, 2021** – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Officer, will participate and host one-on-one investor meetings at the following upcoming investor conferences:

### **Redeye Life Science Day 2021**

**Location:** Hybrid Event

**Date:** Thursday, November 11, 2021

**Type:** Live Presentation

**Time:** 16:30 – 16:50 CET

Live presentations can be viewed via the following link: [www.redeye.se](http://www.redeye.se)

### **H.C. Wainwright 7<sup>th</sup> Annual Israel Conference**

**Location:** Virtual

**Date:** Monday, November 15, 2021

**Type:** Live Presentation & 1x1's

**Time:** 14:00 – 14:30 CET

### **Inv€stival Showcase 2021**

**Location:** London and Virtual

**Dates:** November 8 - 15, 2021

**Type:** In Person 1x1's, Nov 15, 2021

### **Jefferies HealthCare Conference**

**Location:** London and Virtual

**Date:** November 16, 2021

**Type:** In Person 1x1's

### **ØU Life Science Life Science Investor Konference Summit**

**Location:** Copenhagen

**Date:** Wednesday, November 24, 2021

**Type:** Live Presentation & 1x1's

**Time:** 15:50 - 16:20 CET

Presentation can be viewed via the following link: [www.eventbrite.co.uk](http://www.eventbrite.co.uk)

*All presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers to if you wish to attend or Julie Silber if you wish to schedule a meeting with Alligator.*

### **For further information, please contact:**

Julie Silber, Investor Relations

Phone: +46 46-540 82 23

E-mail: [jur@alligatorbioscience.com](mailto:jur@alligatorbioscience.com)

### **About Alligator Bioscience**

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527

with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit <http://www.alligatorbioscience.com>.